Domestic price of ivonib/ivitinib

Ivosidenib/Ivosidenib is a targeted drug used to treat certain types of cancer, especially acute myeloid leukemia (AML) and certain solid tumors. The drug works primarily by inhibiting IDH1 (isocitrate dehydrogenase 1) mutations. IDH1 mutations are common in some tumor cells and can lead to abnormal cell metabolism and promote tumor growth. The mechanism of ivonib is to restore normal cell metabolism by inhibiting the activity of these mutant IDH1 enzymes, thereby inducing apoptosis of cancer cells.

In the United States, ivonib was approved by the U.S. Food and Drug Administration (FDA) in 2018, becoming the first targeted therapy for IDH1 mutations. Clinical trials have shown that the drug has significant efficacy in patients with acute myeloid leukemia carrying IDH1 mutations, improving the patient's remission rate and prolonging survival to a certain extent. In addition, ivonib is also being explored for other types of cancer, including biliary tract cancer.

Regarding the marketing status of avonib in China, as of now, it has obtained marketing authorization in China. According to relevant information from the National Medical Products Administration, the launch of ivonib in China provides a new treatment option for patients, especially those for whom traditional chemotherapy is ineffective or unable to tolerate chemotherapy. The introduction of this drug marks the further development of targeted therapy in the field of tumor treatment in China.

As for the price of ivonib, the specific price may vary depending on the region and medical institution. Generally speaking, the selling price of a single dose of ivonib is higher in the international market, and the domestic price is usually affected by medical insurance policies and market competition. In some cities, the common specifications of Avonib are 0.25g*60 tablets, which cost about RMB 70,000 per box. Since it is not covered by medical insurance, patients can only purchase this drug at their own expense.